Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Molecular Diagnostics to Develop Autism Dx With TCAG Markers

NEW YORK (GenomeWeb News) — CombiMatrix’s molecular diagnostics unit will create an array-based test using biomarkers linked to autism that were developed by the Center for Applied Genomics, the company said today.
 
The company said it will use the markers through a partnership with TCAG in a constitutional genetic array test that will be used to screen for autism and “more than 50 disorders.”
 
One version of the test will be available sometime before the end of the month, and another version, to be created with TCAG, that uses the new autism indicators will be available at the end of the year, CombiMatrix said.    
 
Financial terms of the agreement were not released.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.